A Phase 1 Study of SKB571 in Subjects with Advanced Solid Tumors
This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor .
Solid Malignancies
DRUG: SKB571
Number of subjects achieving Dose-limiting toxicity (DLT), DLT is defined as an adverse event (AE) that meets protocol defined DLT criteria during cycle 1 and is at least possibly related to study drug., From data of initial dose until up to 21 days for treatment
Objective Response Rate (ORR), The sum of the number of cases with Complete Response (CR) and Partial Response (PR) in all treated tumor patients (CR + PR) divided by the total number of cases., Up to 24 months|Progression Free Survival (PFS), Time from start of treatment to progression of disease (PD) or death, whichever occurs first, in patients with tumors., Up to 24 months|Duration of Response (DOR), Time from the start of the first assessment of CR or PR in tumor patients to PD or death due to any reason., Up to 24 months|Overall Survival (OS), Time from start of treatment to death due to any reason., Up to 24 months
This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor.